Ricardo Ruiz-Villaverde1,2, Lourdes Rodriguez-Fernandez-Freire3, Manuel Galán-Gutierrez4, Jose C Armario-HIta5, Leandro Martinez-Pilar6. 1. UGC Dermatología, Hospital Universitario San Cecilio, Granada, Spain. 2. Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain. 3. UGC Dermatología, Hospital Universitario Virgen del Rocio, Sevilla, Spain. 4. UGC Dermatología, Hospital Universitario Reina Sofía, Córdoba, Spain. 5. UGC Dermatología, Hospital Universitario Puerto Real, Cádiz, Spain. 6. UGC Dermatología, Hospital Universitario Carlos Haya, Málaga, Spain.
Abstract
BACKGROUND: Psoriasis is a chronic systemic disease that requires long-term management. Despite data on follow-up studies going back 5 years, little is known about the condition's sustainability based on patient profiles. The aim of this study was to analyze drug survival and discontinuation rates for secukinumab treatment under real-world conditions. PATIENTS AND METHODS: Patients with moderate-to-severe plaque psoriasis treated in the dermatology department of five Spanish medical centers between 2015 and 2019 were included in our retrospective study. Drug survival was assessed with Kaplan-Meier analysis plots and multivariate regression. RESULTS: In total, 171 treated patients were retrospectively recorded and analyzed for 152 weeks (37.40% had been diagnosed with psoriatic arthritis [PsA]). The discontinuation rate in the PsA group was 14.10% vs. 12.10% among those who had no PsA. The mean survival time of discontinuation was 63 weeks for PsA vs. 65 weeks for no PsA (P = 0.913). Secukinumab's estimated mean survival in PsA patients was 86% (estimated mean survival time 130 weeks) vs. 88% (estimated mean survival time of 133 weeks) in non-PsA patients (P = 0.676). CONCLUSION: The mean survival time of patients in secukinumab treatment was comparable in all patient profiles and better than the data found in clinical trials and real-life studies.
BACKGROUND:Psoriasis is a chronic systemic disease that requires long-term management. Despite data on follow-up studies going back 5 years, little is known about the condition's sustainability based on patient profiles. The aim of this study was to analyze drug survival and discontinuation rates for secukinumab treatment under real-world conditions. PATIENTS AND METHODS: Patients with moderate-to-severe plaque psoriasis treated in the dermatology department of five Spanish medical centers between 2015 and 2019 were included in our retrospective study. Drug survival was assessed with Kaplan-Meier analysis plots and multivariate regression. RESULTS: In total, 171 treated patients were retrospectively recorded and analyzed for 152 weeks (37.40% had been diagnosed with psoriatic arthritis [PsA]). The discontinuation rate in the PsA group was 14.10% vs. 12.10% among those who had no PsA. The mean survival time of discontinuation was 63 weeks for PsA vs. 65 weeks for no PsA (P = 0.913). Secukinumab's estimated mean survival in PsA patients was 86% (estimated mean survival time 130 weeks) vs. 88% (estimated mean survival time of 133 weeks) in non-PsA patients (P = 0.676). CONCLUSION: The mean survival time of patients in secukinumab treatment was comparable in all patient profiles and better than the data found in clinical trials and real-life studies.
Authors: Peter Foley; Nick Manuelpillai; Con Dolianitis; Geoffrey D Cains; Eric Mate; Rebecca Tronnberg; Christopher Baker Journal: Australas J Dermatol Date: 2022-07-09 Impact factor: 2.481